Israeli asthma patients under the microscope: Benralizumab's Real-World impact revealed
NCT ID NCT07218172
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 25 times
Summary
This study reviewed medical records of 197 adults in Israel with severe asthma who started taking benralizumab between 2019 and 2024. Researchers looked at how many asthma attacks patients had before and during treatment. The goal was to understand real-world benefits and patient characteristics, not to test a new drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Tel Aviv, Israel
Conditions
Explore the condition pages connected to this study.